Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440368 | 0.79 | BDKRB1 (0.44) | KEAP1NFE2L2 | |
| SCHEMBL13063372 | 0.79 | KEAP1 (0.41) | KEAP1NFE2L2LMNAMEN1TSHR | |
| SCHEMBL12046796 | 0.77 | HTT (0.44) | LMNAMEN1TSHRKMT2AHTT | |
| SCHEMBL13063422 | 0.74 | F10 (0.42) | — | |
| SCHEMBL13063135 | 0.73 | CYP3A4 (0.32) | — | |
| SCHEMBL2579003 | 0.73 | CA14 (0.42) | LMNAL3MBTL1MEN1TSHRKMT2A | |
| SCHEMBL12012115 | 0.72 | BDKRB1 (0.40) | LMNAMEN1TSHRKMT2AHTT | |
| SCHEMBL13063435 | 0.71 | BRD4 (0.40) | — | |
| SCHEMBL13063136 | 0.71 | LMNA (0.35) | LMNAMEN1TSHRKMT2A | |
| SCHEMBL13063117 | 0.70 | CYP3A4 (0.40) | LMNAMEN1TSHRKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | KEAP1 2284/4885NFE2L2 3482/4885PPARG 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.